Results 51 to 60 of about 73,039 (208)

Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis

open access: yesJK Science, 2022
Janus kinase (JAK) and signal transducer and activator of transcription (STAT) signalling has been established to have pathophysiological role in multiple disease states, such as myeloproliferative neoplasms, rheumatoid arthritis, inflammatory bowel ...
Vishal R. Tandon, Annil Mahajan
doaj  

Targeting kinases with anilinopyrimidines: Discovery of N-phenyl-N'-[4-(pyrimidin-4-ylamino)phenyl]urea derivatives as selective inhibitors of class III receptor tyrosine kinase subfamily [PDF]

open access: yes, 2015
Kinase inhibitors are attractive drugs/drug candidates for the treatment of cancer. The most recent literature has highlighted the importance of multi target kinase inhibitors, although a correct balance between specificity and non-specificity is ...
Chilin, Adriana   +5 more
core   +2 more sources

Cytokine release syndrome in COVID-19 patients, a new scenario for an old concern. The fragile balance between infections and autoimmunity [PDF]

open access: yes, 2020
On 7 January 2020, researchers isolated and sequenced in China from patients with severe pneumonitis a novel coronavirus, then called SARS-CoV-2, which rapidly spread worldwide, becoming a global health emergency.
Diamanti, A. P.   +4 more
core   +2 more sources

Driving chronicity in rheumatoid arthritis: perpetuating role of myeloid cells [PDF]

open access: yes, 2018
Acute inflammation is a complex and tightly regulated homeostatic process that includes leukocyte migration from the vasculature into tissues to eliminate the pathogen/injury, followed by a pro-resolving response promoting tissue repair.
Achuthan   +115 more
core   +1 more source

Treatments for actinic prurigo: A case report with upadacitinib and systematic review

open access: yesSAGE Open Medical Case Reports
This study aims to evaluate treatments for actinic prurigo, a chronic, photosensitive dermatosis disproportionately affecting Indigenous populations.
Jonah W. Perlmutter   +2 more
doaj   +1 more source

The specificities of small molecule inhibitors of the TGF beta and BMP pathways [PDF]

open access: yes, 2011
Small molecule inhibitors of type 1 receptor serine threonine kinases (ALKs1-7), the mediators of TGF beta and BMP signals, have been employed extensively to assess their physiological roles in cells and organisms. While all of these inhibitors have been
Sapkota, Gopal P.   +2 more
core   +3 more sources

Consensus on the Clinical Approach to Moderate-to-Severe Atopic Dermatitis in Spain: A Delphi Survey [PDF]

open access: yes, 2020
Background. The purpose of this study was to gather information on the current assessment and management of patients with moderate-to-severe AD in routine daily practice. Methods.
Armario Hita, José Carlos   +9 more
core   +3 more sources

Rapid resolution of non-segmental vitiligo in a patient treated with abrocitinib: A case report

open access: yesSAGE Open Medical Case Reports
Vitiligo is a common, autoimmune, depigmenting disorder of the skin. Janus Kinase inhibitors have emerged as promising topical and oral therapeutic options for vitiligo.
Seyyon Satkunanathan   +3 more
doaj   +1 more source

Risk Factors that Impact Treatment with Oral Janus Kinase Inhibitors Among Adult Patients with Atopic Dermatitis: A Nationwide Registry Study

open access: yesActa Dermato-Venereologica
The European Medicines Agency recently limited the use of oral Janus kinase inhibitors in certain patient populations, including those with atopic dermatitis.
Ida Vittrup   +4 more
doaj   +1 more source

Activation of tyrosine kinases by mutation of the gatekeeper threonine. [PDF]

open access: yes, 2008
Protein kinases targeted by small-molecule inhibitors develop resistance through mutation of the gatekeeper threonine residue of the active site. Here we show that the gatekeeper mutation in the cellular forms of c-ABL, c-SRC, platelet-derived growth ...
Azam, Mohammad   +4 more
core   +1 more source

Home - About - Disclaimer - Privacy